Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2000-4-18
pubmed:abstractText
The effects of 6-mercaptopurine (6-MP) are mediated via its intracellular conversion to 6-thioguanine (6-TG) and 6-methylmercaptopurine (6-MMP) nucleotide metabolites, the latter genetically controlled by thiopurine methyltransferase (TPMT). We sought to determine optimal therapeutic 6-MP metabolite levels and their correlation with medication-induced toxicity and TPMT genotype.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0016-5085
pubmed:author
pubmed:issnType
Print
pubmed:volume
118
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
705-13
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10734022-6-Mercaptopurine, pubmed-meshheading:10734022-Adolescent, pubmed-meshheading:10734022-Child, pubmed-meshheading:10734022-Child, Preschool, pubmed-meshheading:10734022-Dose-Response Relationship, Drug, pubmed-meshheading:10734022-Female, pubmed-meshheading:10734022-Genotype, pubmed-meshheading:10734022-Humans, pubmed-meshheading:10734022-Immunosuppressive Agents, pubmed-meshheading:10734022-Infant, pubmed-meshheading:10734022-Inflammatory Bowel Diseases, pubmed-meshheading:10734022-Leukopenia, pubmed-meshheading:10734022-Liver, pubmed-meshheading:10734022-Male, pubmed-meshheading:10734022-Mesalamine, pubmed-meshheading:10734022-Methyltransferases, pubmed-meshheading:10734022-Prospective Studies, pubmed-meshheading:10734022-Thioguanine, pubmed-meshheading:10734022-Treatment Outcome
pubmed:year
2000
pubmed:articleTitle
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
pubmed:affiliation
Division of Gastroenterology and Nutrition, University of Montréal, Montréal, Québec, Canada.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't